期刊
ARCHIVES OF PHARMACAL RESEARCH
卷 38, 期 5, 页码 575-584出版社
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-015-0569-8
关键词
Rheumatoid arthritis; Interleukin-6 (IL-6); Disease-modifying anti-rheumatic drugs (DMARDs); Tumor necrosis factor alpha (TNF-alpha); Tocilizumab (TCZ)
资金
- Ministry for Food, Agriculture, Forest, and Fisheries of Republic of Korea [114010031HD030]
- Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry & Fisheries (iPET), Republic of Korea [114010031HD030] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by polyarthritis. Numerous agents with varying mechanisms are used in the treatment of RA, including non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and some biological agents. Studies to uncover the cause of RA have recently ended up scrutinizing the importance of proinflammatory cytokine such as tumor necrosis factor a (TNF-alpha) and interleukin (IL)-6 in the pathogenesis of RA. TNF-alpha inhibitors are increasingly used to treat RA patients who are non-responsive to conventional anti-arthritis drugs. Despite its effectiveness in a large patient population, up to two thirds of RA patients are found to be partially responsive to anti-TNF therapy. Therefore, agents targeting IL-6 such as tocilizumab (TCZ) attracted significant attention as a promising agent in RA treatment. In this article, we review the mechanism of anti-IL-6 in the treatment of RA, provide the key efficacy and safety data from clinical trials of approved anti-IL-6, TCZ, as well as six candidate IL-6 blockers including sarilumab, ALX-0061, sirukumab, MEDI5117, clazakizumab, and olokizumab, and their future perspectives in the treatment of RA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据